<a href="https://laohu8.com/S/MAZE">Maze Therapeutics</a> reports third quarter 2025 results and pipeline progress
Maze Therapeutics Inc. reported cash, cash equivalents, and marketable securities of $383.9 million as of September 30, 2025, compared to $196.8 million at December 31, 2024. The company expects its current cash position to fund operations into 2028. No license revenue was recognized for the three and nine months ended September 30, 2025, compared to $2.5 million and $167.5 million, respectively, for the same periods in 2024, mostly due to a $150.0 million upfront payment from a 2024 license agreement with Shionogi & Co., Ltd. Research and development expenses were $25.2 million and $80.9 million for the three and nine months ended September 30, 2025, up from $19.9 million and $61.3 million in the prior year periods, reflecting increased clinical and manufacturing costs and personnel expenses. Key business developments included an oversubscribed private placement in September 2025 raising approximately $150.0 million and the appointment of Misbah Tahir as chief financial officer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570885-en) on November 06, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.